Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR1950] to FOXO3A
- Suitable for: WB, Flow Cyt
- Knockout validated
- Reacts with: Rat, Human
Product nameAnti-FOXO3A antibody [EPR1950]
See all FOXO3A primary antibodies
DescriptionRabbit monoclonal [EPR1950] to FOXO3A
Tested applicationsSuitable for: WB, Flow Cytmore details
Unsuitable for: IHC-P or IP
Species reactivityReacts with: Rat, Human
Synthetic peptide within Human FOXO3A aa 650-750 (C terminal). The exact sequence is proprietary.
Database link: O43524
- MCF7 and SH-SY5Y cell lysates, HeLa cells
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Storage instructionsShipped at 4°C. Upon delivery aliquot. Store at -20°C. Stable for 12 months at -20°C.
Storage bufferpH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, 50% Tissue culture supernatant
Concentration information loading...
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab109629 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/10000. Detects a band of approximately 90 kDa (predicted molecular weight: 71 kDa).|
|Flow Cyt||Use at an assay dependent concentration.|
FunctionTranscriptional activator which triggers apoptosis in the absence of survival factors, including neuronal cell death upon oxidative stress. Recognizes and binds to the DNA sequence 5'-[AG]TAAA[TC]A-3'.
Involvement in diseaseNote=A chromosomal aberration involving FOXO3 is found in secondary acute leukemias. Translocation t(6;11)(q21;q23) with MLL/HRX.
Sequence similaritiesContains 1 fork-head DNA-binding domain.
modificationsIn the presence of survival factors such as IGF-1, phosphorylated on Thr-32 and Ser-253 by AKT1/PKB. This phosphorylated form then interacts with 14-3-3 proteins and is retained in the cytoplasm. Survival factor withdrawal induces dephosphorylation and promotes translocation to the nucleus where the dephosphorylated protein induces transcription of target genes and triggers apoptosis. Although AKT1/PKB doesn't appear to phosphorylate Ser-315 directly, it may activate other kinases that trigger phosphorylation at this residue. Phosphorylated by STK4 on Ser-209 upon oxidative stress, which leads to dissociation from YWHAB/14-3-3-beta and nuclear translocation. Phosphorylated by PIM1.
Cellular localizationCytoplasm > cytosol. Nucleus. Translocates to the nucleus upon oxidative stress and in the absence of survival factors.
- Information by UniProt
- AF6q21 antibody
- AF6q21 protein antibody
- DKFZp781A0677 antibody
All lanes : Anti-FOXO3A antibody [EPR1950] (ab109629)
Lane 1 : Wild-type HEK 293 whole cell lysate
Lane 2 : FOXO3 knockout HEK 293 whole cell lysate
Lane 3 : Hela whole cell lysate
Lane 4 : Jurkat whole cell lysate
Lysates/proteins at 20 µg per lane.
Predicted band size: 71 kDa
Lanes 1 - 4: Merged signal (red and green). Green - ab109629 observed at 71 kDa. Red - loading control, ab8245, observed at 37 kDa.
ab109629 was shown to recognize FOXO3A in wild-type HEK 293 cells as signal was lost at the expected MW in FOXO3 knockout cells. Additional cross-reactive bands were observed in the wild-type and knockout cells. Wild-type and FOXO3 knockout samples were subjected to SDS-PAGE. The membrane was blocked with 3% Milk. Ab109629 and ab8245 (Mouse anti-GAPDH loading control) were incubated overnight at 4°C at 1/1000 dilution and 1/20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed ab216773 and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed ab216776 secondary antibodies at 1/20000 dilution for 1 hour at room temperature before imaging.
All lanes : Anti-FOXO3A antibody [EPR1950] (ab109629) at 1/1000 dilution
Lane 1 : MCF7 cell lysate
Lane 2 : SH-SY5Y cell lysate
Lysates/proteins at 10 µg per lane.
Predicted band size: 71 kDa
Flow Cytometry analysis of HeLa (human cervix adenocarcinoma) cells labeling FOXO3A with unpurified ab109629 at 1/150 dilution(10ug/ml) (red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. A Goat anti rabbit IgG (Alexa Fluor® 488)(1/2000 dilution) was used as the secondary antibody. Rabbit monoclonal IgG (Black) was used as the isotype control, cells without incubation with primary antibody and secondary antibody (Blue) were used as the unlabeled control.
ab109629 has been referenced in 10 publications.
- Li M et al. miR-629 targets FOXO3 to promote cell apoptosis in gastric cancer. Exp Ther Med 19:294-300 (2020). PubMed: 31853302
- Zhao Y et al. Leucine Improved Growth Performance, Muscle Growth, and Muscle Protein Deposition Through AKT/TOR and AKT/FOXO3a Signaling Pathways in Hybrid Catfish Pelteobagrus vachelli × Leiocassis longirostris. Cells 9:N/A (2020). PubMed: 32019276
- Wang S et al. Circulating IGF-1 promotes prostate adenocarcinoma via FOXO3A/BIM signaling in a double-transgenic mouse model. Oncogene 38:6338-6353 (2019). PubMed: 31312023
- Lu Z et al. Dracorhodin perchlorate induces apoptosis and G2/M cell cycle arrest in human esophageal squamous cell carcinoma through inhibition of the JAK2/STAT3 and AKT/FOXO3a pathways. Mol Med Rep 20:2091-2100 (2019). PubMed: 31322237
- Zhang Y et al. Treatment with placental growth factor attenuates myocardial ischemia/reperfusion injury. PLoS One 13:e0202772 (2018). PubMed: 30212490
- Liu S et al. FoxO3a plays a key role in the protective effects of pomegranate peel extract against amikacin-induced ototoxicity. Int J Mol Med 40:175-181 (2017). PubMed: 28560451
- Kumazoe M et al. PDE3 inhibitor and EGCG combination treatment suppress cancer stem cell properties in pancreatic ductal adenocarcinoma. Sci Rep 7:1917 (2017). PubMed: 28507327
- Kumazoe M et al. The FOXO3/PGC-1ß signaling axis is essential for cancer stem cell properties of pancreatic ductal adenocarcinoma. J Biol Chem 292:10813-10823 (2017). PubMed: 28507102
- Xiao Q et al. Mild hypothermia pretreatment protects against liver ischemia reperfusion injury via the PI3K/AKT/FOXO3a pathway. Mol Med Rep 16:7520-7526 (2017). PubMed: 28944825
- Hu T et al. Reprogramming ovarian and breast cancer cells into non-cancerous cells by low-dose metformin or SN-38 through FOXO3 activation. Sci Rep 4:5810 (2014). WB, ICC/IF ; Human . PubMed: 25056111